Acelyrin Inc (NASDAQ: SLRN) has experienced a decline in its stock price by -15.73 compared to its previous closing price of 2.48. However, the company has seen a fall of -13.64% in its stock price over the last five trading days. globenewswire.com reported 2025-05-13 that LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) — ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction.
Is It Worth Investing in Acelyrin Inc (NASDAQ: SLRN) Right Now?
The 36-month beta value for SLRN is at 1.10. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLRN is 73.31M, and currently, shorts hold a 4.87% of that float. The average trading volume for SLRN on May 14, 2025 was 1.52M shares.
SLRN’s Market Performance
SLRN’s stock has seen a -13.64% decrease for the week, with a -6.28% drop in the past month and a 2.96% gain in the past quarter. The volatility ratio for the week is 10.00%, and the volatility levels for the past 30 days are at 7.54% for Acelyrin Inc The simple moving average for the past 20 days is -10.80% for SLRN’s stock, with a -44.26% simple moving average for the past 200 days.
Analysts’ Opinion of SLRN
Many brokerage firms have already submitted their reports for SLRN stocks, with H.C. Wainwright repeating the rating for SLRN by listing it as a “Neutral.” The predicted price for SLRN in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on August 14, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see SLRN reach a price target of $13. The rating they have provided for SLRN stocks is “Overweight” according to the report published on July 08th, 2024.
Wells Fargo gave a rating of “Equal Weight” to SLRN, setting the target price at $11 in the report published on December 13th of the previous year.
SLRN Trading at -15.30% from the 50-Day Moving Average
After a stumble in the market that brought SLRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.17% of loss for the given period.
Volatility was left at 7.54%, however, over the last 30 days, the volatility rate increased by 10.00%, as shares sank -4.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.30% lower at present.
During the last 5 trading sessions, SLRN fell by -13.64%, which changed the moving average for the period of 200-days by -68.95% in comparison to the 20-day moving average, which settled at $2.34. In addition, Acelyrin Inc saw -33.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLRN starting from Kim Mina, who sale 17,986 shares at the price of $2.74 back on Mar 17 ’25. After this action, Kim Mina now owns 671,753 shares of Acelyrin Inc, valued at $49,354 using the latest closing price.
Murugan Amar, the Chief Legal Officer of Acelyrin Inc, sale 3,913 shares at $2.74 during a trade that took place back on Mar 17 ’25, which means that Murugan Amar is holding 121,587 shares at $10,737 based on the most recent closing price.
Stock Fundamentals for SLRN
The total capital return value is set at -0.68. Equity return is now at value -44.54, with -40.24 for asset returns.
Based on Acelyrin Inc (SLRN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -48.47.
Currently, EBITDA for the company is -247.8 million with net debt to EBITDA at 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.10.
Conclusion
In conclusion, Acelyrin Inc (SLRN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
